Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 617-625

  Bruzzese, Francesca ^a   Di Gennaro, Elena ^a   Avallone, Antonio ^a   Pepe, Stefano ^a   Arra, Claudio ^a   Caraglia, Michele ^a   Tagliaferri, Pierosandro ^b   Budillon, Alfredo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; STAT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544451593     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1671     Document Type: Article

References (55)

1. Forastiere AA. Induction and adjuvant chemotherapy for head and neck cancer: future perspectives. Acta Otorhinolaryngol Belg 1999;53:277-80.
2. Sidransky D. Cancer of the head and neck. In: De Vita WS, Hellman S, Jr., Rosemberg SA, editors. Cancer: principles & practice of oncology. Philadelphia: Lippincott; 2001. p. 789-96.
3. Etienne MC, Pivot X, Formento JL, et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999;79:1864-9.
4. Xian CJ, Zhou XF. EGF family of growth factors: essential roles and functional redundancy in the nerve system. Front Biosci 2004;9:85-92.
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
6. Lango MN, Shin DM, Grandis JR. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol 2001;13:168-75.
7. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
8. Wilkinson MG, Millar JB. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 2000;14:2147-57.
9. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene 1998;17:1457-62.
10. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
11. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-9.
12. CIP1;WAF1 in the antiproliferative effect of ZD1839 ("Iressa"), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003;195:139-50.
13. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
14. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-46.
15. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8.
16. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial. INTACT 2. J Clin Oncol 2004;22:785-94.
17. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial. INTACT1. J Clin Oncol 2004;22:777-84.
18. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
20. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
21. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
22. Lee JW, Soung YH, Kim SY, Nam HK, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-82.
23. Uze G, Lutfalla G, Mogensen KE. α and β Interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995;15:3-26.
24. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489-99.
25. Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci U S A 1994;91:1198-205.
26. Vlock DR, Andersen J, Kalish LA, et al. Phase II trial of interferon-α in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 1996;19:433-42.
27. Lotan R, Dawson MI, Zou CC, Jong L, Lotan D, Zou CP. Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 1995;55:232-6.
28. Toma S, Raffo P, Isnardi L, Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol 1999;10 Suppl 5:S95-102.
29. Kirkwood J. Cancer immunotherapy: the interferon-α experience. Semin Oncol 2002;29:18-26.
30. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002;9:16-21.
31. Tagliaferri P, Caraglia M, Budillon A, et al. New pharmacokinetic and pharmacodynamic tools for interferon-α (IFN-α) treatment of human cancer. Cancer Immunol Immunother 2005;54:1-10.
32. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem 1997;272:28779-85.
33. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95.
34. Budillon A, Tagliaferri P, Caraglia M, et al. Upregulation of epidermal growth factor receptor induced by α-interferon in human epidermoid cancer cells. Cancer Res 1991;51:1294-9.
35. Caraglia M, Leardi A, Corradino S, et al. α-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 1995;61:342-7.
36. Tagliaferri P, Caraglia M, Muraro R, et al. Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. Anticancer Drugs 1994;5:379-93.
37. Caraglia M, Abbruzzese A, Leardi A, et al. Interferon-α induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 1999;6:773-80.
38. Caraglia M, Tagliaferri P, Marra M, et al. EGF activates an inducible survival response via the RAS->Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003;10:218-29.
39. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
40. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002;62:6909-15.
41. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
42. Sommer K, Peters SO, Robins IH, et al. A preclinical model for experimental chemotherapy of human head and neck cancer. Int J Oncol 2001;18:1145-9.
43. Teicher BA. In vivo tumor response end points. In: Teicher B, editor. Tumor models in cancer research. Totowa: Humana Press: 2002. p. 593-616.
44. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-23.
45. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
46. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
47. Solorzano CC, Hwang R, Baker CH, et al. Administration of optimal biological dose and schedule of interferon α combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003;9:1858-67.
48. Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ("Iressa") is independent of EGFR expression level. J Cell Physiol 2004;198:259-68.
49. Johnson BE, Janne PA. Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 2005;23:6813-6.
50. Qu XJ, Yang JL, Russell PJ, Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-α treatment. J Urol 2004;172:733-8.
51. Yang JL, Qu XJ, Russell PJ, Goldstein D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon α. Gut 2004;53:123-9.
52. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon α/β promotes cell survival by activating nuclear factor κB through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001;276:13756-61.
53. Caraglia M, Vitale G, Marra M, Budillon A, Tagliaferri P, Abbruzzese A. α-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci 2004;5:475-85.
54. Marra F, Choudhury GG, Abboud HE. Interferon-γ-mediated activation of STAT1α regulates growth factor-induced mitogenesis. J Clin Invest 1996;98:1218-30.
55. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11:7480-9.